Eli Lilly completes acquisition of Sigilon Therapeutics

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Sigilon Therapeutics (SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. Sigilon’s common stock has been delisted from the NASDAQ Global Select Market and will be deregistered under the Securities Exchange Act of 1934, as amended.